Featured news from NHIVNA
HIV-related news from NAM
Daclatasvir works well against hepatitis C either with interferon or in all-oral regimen
Liz Highleyman, 2013-10-10 06:00:00
A short 12- or 16-week triple regimen of daclatasvir plus pegylated interferon/ribavirin cured more people than a 24-week course of pegylated interferon/ribavirin alone, whilst an interferon-free regimen containing daclatasvir, asunaprevir and BMS-791325 produced sustained response rates of around 90%, researchers reported at the IDWeek 2013 conference last week in San Francisco.
The advent of direct-acting antiviral agents has brought about a new era of treatment for hepatitis C virus (HCV). These agents will first be used as add-ons to interferon-based therapy, and later in all-oral regimens that enable patients to avoid the difficult side-effects of interferon.
Source:1
